Skip Navigation LinksHome > February 2003 - Volume 98 - Issue 2 > Neuroprotective Effect of Urinary Trypsin Inhibitor against...
Anesthesiology:
Laboratory Investigations

Neuroprotective Effect of Urinary Trypsin Inhibitor against Focal Cerebral Ischemia–Reperfusion Injury in Rats

Yano, Toshiyuki M.D., Ph.D.*; Anraku, Sakiko M.D.†; Nakayama, Ryosuke M.D.‡; Ushijima, Kazuo M.D., Ph.D.§

Free Access
Article Outline
Collapse Box

Author Information

Collapse Box

Abstract

Background: Acute inflammatory reactions cause neuronal damage in cerebral ischemia–reperfusion. Urinary trypsin inhibitor (UTI), a serine protease inhibitor, is cytoprotective against ischemia–reperfusion injury in the liver, intestine, kidney, heart, and lung through its antiinflammatory activity. Neuroprotective action of UTI on transient global cerebral ischemia has been documented. This is the first study to determine whether UTI is neuroprotective against transient focal cerebral ischemia.
Methods: Adult male Wistar rats were randomly assigned to the following treatment groups: 0.9% saline (control, n = 9); 100,000 U/kg UTI (n = 9); and 300,000 U/kg UTI (n = 9). Treatments were performed intravenously 10 min before right middle cerebral artery occlusion for 2 h and subsequent reperfusion. Ninety-six hours after the onset of reperfusion, the motor neurologic deficit and the cerebral infarct size were evaluated. Furthermore, immunohistochemical staining for myeloperoxidase and nitrotyrosine to count infiltrating neutrophils and nitrated cells, respectively, was performed on the brain sections.
Results: Infarct volume in the 300,000 U/kg UTI group was smaller than in the 100,000 U/kg UTI and saline control groups (P < 0.05). Treatment with 300,000 U/kg UTI showed a trend to improve neurologic outcome but did not reach statistical significance (P = 0.0693). The significant decrease in neutrophil infiltration was observed in the ischemic hemisphere treated with 300,000 U/kg UTI compared with saline control (P < 0.05). Nitrotyrosine deposition in the ischemic hemisphere was significantly reduced in the 300,000 U/kg UTI group compared with saline control and 100,000 U/kg UTI groups (P < 0.05).
Conclusions: Intravenous pretreatment with 300,000 U/kg UTI reduces focal ischemia–reperfusion injury in the rat brain, potentially opening a novel therapeutic avenue for the treatment of cerebral ischemia.
STROKE is one of the major complications in the perioperative period of neurosurgery and cardiovascular surgery. Although restoration of cerebral blood flow in the ischemic territory has been feasible by thrombolytic agents such as the tissue plasminogen activator, the likelihood of reperfusion injury represented by brain edema and hemorrhage especially increases beyond an optimal therapeutic window (within 3 h of symptom onset) of the thrombolytic treatment. 1,2 Prophylactic pharmacological interventions for neuroprotection against cerebral ischemia–reperfusion injuries could bring about significant benefits in patients undergoing those surgeries and the following intensive care. However, efficacious and safe neuroprotective agents have not yet been established.
Ample accumulating evidence suggests that an acute inflammatory response associated with cerebral ischemia–reperfusion contributes to the development of brain damage. 3 Because the inflammatory response takes place immediately and lasts for at least a few days after ischemic brain injury, 4 these responses would be a promising target for antiinflammatory approaches to neuroprotection. Urinary trypsin inhibitor (UTI; ulinastatin), a serine protease inhibitor derived from human urine, has an antiinflammatory activity to suppress the infiltration of neutrophils and the release of elastase and chemical mediators from neutrophils. 5–10 Recent studies have shown that UTI may be cytoprotective against ischemia–reperfusion injury in the liver, intestine, kidney, heart, and lung. 5,11–14 Neuroprotective action of UTI on global ischemia–reperfusion in the brain has been documented. 15 However, the effects of UTI on focal cerebral ischemia–reperfusion injury remain to be elucidated. The purpose of this study was to identify whether pretreatment with UTI reduces cerebral injury due to transient middle cerebral artery occlusion (MCAO).
Back to Top | Article Outline

Materials and Methods

Subjects, Preparation, and Laser Doppler Flowmetry
We performed all animal care procedures in this study according to the Guidelines for Animal Experiments of the Kumamoto University School of Medicine (Kumamoto, Japan). The Animal Care and Use Committee for our institute approved the study protocol. We used adult male Wistar rats weighing between 250 and 330 g. The animals were given free access to food and water. At the time of the experiment, the animal was anesthetized with 5% isoflurane in a mixture of nitrous oxide and oxygen (fraction of inspired oxygen [Fio2], 0.33) in a box, and anesthesia was maintained at 1.5% isoflurane in the same gas mixture using a face mask. The pericranial temperature was continuously monitored between the right temporal muscle and temporal bone with a tissue-implantable thermocouple microprobe (IT-14; Physitemp Instruments Inc., Clifton, NJ) and maintained at 37.5 ± 0.5°C during the surgery, brain ischemia, and recovery from anesthesia with the use of a temperature controller (TCAT-1A; Physitemp Instruments Inc.) and a radiant heating lamp. The tail artery was cannulated for monitoring of arterial pressure and analysis of arterial blood gases, glucose, and hematocrit. The animal was placed on a stereotaxic instrument (Model 900; David Kopf, Tujunga, CA) in the prone position, and a burr hole (diameter, 2 mm) was drilled in the right cranium at 2 mm posterior and 6 mm lateral to the bregma over the middle cerebral artery (MCA) territory. An acrylic guide cannula (OD, 2 mm; ID, 1 mm; length, 6 mm; NS Sheath; Advance Co. Ltd., Tokyo, Japan) was placed perpendicularly on the surface of the intact dura and fixed to the cranium using acrylic cement. One end of the guide cannula has a transparent septum, which directly comes in contact with the dura. The guide cannula was filled with distilled water, and a laser Doppler flowmetry probe (diameter, 1 mm; NSS; Advance Co. Ltd.) connected to a laser Doppler flowmeter (ALF 2100; Advance Co. Ltd.) was inserted until the tip reached the septum of the cannula to allow for continuous measurement of the regional cerebral blood flow (rCBF). The steady state baseline rCBF value was measured before ischemia and was defined to be 100%. The rCBF values are expressed as a percentage of the baseline value (%rCBF).
Back to Top | Article Outline
Middle Cerebral Artery Occlusion
The right MCA was occluded for 2 h using our modification of an intraluminal filament method as previously described by Yamada et al.16 In brief, the right common carotid artery (CCA) was exposed through a midline neck incision, and the right external carotid artery (ECA) was ligated and cut at a site 3 mm distal to the bifurcation of the CCA. After the extracranial branch of the ECA was coagulated and cut, a microvascular clip was placed across the CCA. A silicon-coated 4-0 nylon monofilament suture was then inserted via a small incision in the ECA and advanced into the internal carotid artery until resistance was felt, so that the leading tip of the filament occluded the origin of the right MCA. The microvascular clip was removed, and the incision was closed. Achievement of MCAO was confirmed by both a reduction of 50% or more in rCBF to the baseline value 17 and a counterclockwise circling movement due to paresis of the left limbs 20 min after the emergence of anesthesia. After 120 min of MCA occlusion, the rats were reanesthetized, and the wound was reopened. Reperfusion of the MCA was initiated by removing the MCA occlusive filament and was ascertained by restoration of rCBF. The incision was closed, and the tail arterial catheter and laser Doppler flowmetry probe were removed. The pericranial temperature was kept at 37.5 ± 0.5°C until the rats recovered from anesthesia completely. The temperature probe was removed, and the rats were then returned to cages in a 25°C-controlled environment. Free access to food and water was allowed until the rats were sacrificed.
Back to Top | Article Outline
Experimental Design
Twenty-seven rats were randomly allocated to one of three groups to be treated with 0.9% saline (control, n = 9), 100,000 U/kg UTI (n = 9), or 300,000 U/kg UTI (n = 9). UTI (Mochida Pharmaceutical Co., Ltd, Tokyo, Japan) was dissolved in distilled water. Saline or UTI, 0.5 ml in volume, was intravenously administered via the left external jugular vein 10 min before the initiation of MCAO. All outcome variables were obtained 96 h after the onset of reperfusion. The rats not surviving for 96 h were excluded from the study.
Back to Top | Article Outline
Assessment of Motor Neurologic Deficit
Motor neurologic deficits were evaluated 96 h following MCAO in a blind fashion using a five-point scoring system previously described by Mokudai et al.18: 0 = no observable deficit; 1 = forelimb flexion; 2 = forelimb flexion and decreased resistance to lateral push; 3 = forelimb flexion, decreased resistance to lateral push, and unilateral circling; 4 = forelimb flexion and being unable or difficult to ambulate.
Back to Top | Article Outline
Quantification of Infarct Area and Volume
After the neurologic assessment, the rats were sacrificed under intraperitoneal pentobarbital anesthesia (100 mg/kg) and were then perfused transcardially with heparinized normal saline (4 U/ml). The brains were rapidly removed and sliced at 2–14 mm posterior to the frontal pole into six 2-mm-thick coronal sections using a rat brain slicer (RBS-02; Neuroscience, Inc., Tokyo, Japan). The sections were immersed in 1% 2,3,5-triphenyltetrazolium chloride (TTC; Research Organics, Inc., Cleveland, OH) dissolved in phosphate-buffered saline (PBS; pH 7.4) and incubated at room temperature for 30 min, and then they were fixed in 10% neutral buffered formalin overnight. Infarct size was evaluated by an inspector blinded to intervention according to the method described by Yang et al.19 Briefly, the rostral sides of each fixed section were directly scanned with a flatbed color scanner (OPAL ultra; Heidelberg Japan, Tokyo, Japan) linked with a computer (Power Mac G3; Apple Japan, Inc., Tokyo, Japan) and controlled with supplied software (LinoColor Elite, version 5.1.7; Heidelberg Japan). The margins of the infarct area in the captured digital images were manually outlined, and a pixel-based area calculation was performed using NIH Image 1.61 (National Institutes of Health, Bethesda, MD). The total infarct volume was calculated by summing the infarct area in each section and multiplying by the section thickness.
Back to Top | Article Outline
Histopathology and Immunohistochemistry
After the scanning for infarct quantification, the sections were dehydrated with graded alcohols, embedded in paraffin, and sliced into 5-μm-thick coronal sections. Hematoxylin and eosin (HE) staining was performed to identify the lesion.
Back to Top | Article Outline
Antisera.
Rabbit polyclonal antibodies against myeloperoxidase (1:200 dilution; Neo Markers, Fremont, CA) were used to visualize polymorphonuclear neutrophils (PMNs). Nitrotyrosine was detected with mouse monoclonal antibodies (1:100 dilution; Upstate Biotechnology, Lake Placid, NY).
Back to Top | Article Outline
Immunostaining Procedure.
We used an avidin-biotinylated enzyme complex system (Vectastain Universal Elite ABC kit; Vector Laboratories, Burlingame, CA). In brief, sections on the slides were dehydrated with graded alcohols, washed in PBS, and then quenched with 3% H2O2 in PBS. The sections were subsequently preincubated for 30 min in a solution containing 2.5% normal horse serum to block nonspecific binding of biotinylated antibody. The sections were then incubated with rabbit polyclonal antimyeloperoxidase antibody or mouse monoclonal antinitrotyrosine antibody in 2.5% normal horse serum at 4°C overnight. After the primary incubation, the sections were rinsed in PBS and subsequently incubated with the biotinylated secondary antibody for 30 min. The sections were then rinsed and incubated with avidin-biotinylated peroxidase conjugate for 30 min. They were finally colorized with diaminobenzidine and H2O2 and then counterstained with methyl green acetate. Negative control staining was performed with normal rabbit or mouse sera as a substitute for the primary antimyeloperoxidase or antinitrotyrosine antibody, respectively.
Back to Top | Article Outline
Polymorphonuclear Neutrophil and Nitrotyrosine-positive Cell Counts.
The number of myeloperoxidase- or nitrotyrosine-positive cells was counted at ×200 magnification in the brain parenchyma of the entire ischemic hemisphere at approximately 6 mm from the frontal pole in a blind fashion.
Back to Top | Article Outline
Statistics
Values are expressed as mean ± SD. Body weight, hematocrit, blood glucose, infarct volume, and immunoreactive cell counts were analyzed using one-way analysis of variance. The Tukey-Kramer multiple comparison procedure was then used to determine which pairs of means differed. Differences in mean arterial pressure, arterial blood gases, pericranial temperature, and %rCBF were analyzed using repeated-measures analysis of variance. The Kruskal-Wallis test was used to test the difference in motor neurologic scores. A P value less than 0.05 was defined as significant.
Back to Top | Article Outline

Results

One animal from the 100,000 U/kg UTI group died of subarachnoid hemorrhage early after the onset of reperfusion and was excluded from the study.
Table 1
Table 1
Image Tools
Physiologic variables in all the groups are shown in table 1. Initial body weight, hematocrit, and blood glucose concentration were not significantly different between the saline, 100,000 U/kg UTI, and 300,000 U/kg UTI treatment groups. Mean arterial pressure, arterial blood gases, and pericranial temperature did not differ significantly among the three treatment groups.
Fig. 1
Fig. 1
Image Tools
Figure 1 shows the changes in %rCBF over the MCA territory through ischemia and reperfusion. All the experimental groups exhibited a reduction of %rCBF by approximately 70% during MCAO. After 120 min of MCAO, the MCA occlusive filament was withdrawn, and %rCBF was restored and reached to over the 100% level. There were no significant differences in %rCBF among the three groups (P = 0.4317).
Fig. 2
Fig. 2
Image Tools
Figure 2 exhibits the motor neurologic scores at 96 h following 2 h of MCAO. All the animals had some motor neurologic deficits at this time point. In the saline and 100,000 U/kg UTI treatment groups, scores from individual animals were distributed between 2 and 4 (median, 3). On the other hand, the distribution of scores from individual animals treated with 300,000 U/kg UTI was between 1 and 3 (median, 2). However, the difference in neurologic scores among the three treatment groups did not reach a significant level (P = 0.0693). Body weight loss determined at 96 h after MCAO was similar in all the experimental groups (table 1).
Fig. 3
Fig. 3
Image Tools
Fig. 4
Fig. 4
Image Tools
Effects of UTI treatment on the infarct size 96 h after 2 h of MCAO are shown in figures 3 and 4. The total infarct volume was 223 ± 62 mm3 in saline control animals. Treatment with 300,000 U/kg UTI significantly reduced the total infarct volume (119 ± 50 mm3) by approximately 50% compared with saline treatment, whereas treatment with 100,000 U/kg UTI showed no significant reducing effects on the total infarct volume (199 ± 50 mm3).
Fig. 5
Fig. 5
Image Tools
The infiltration of PMNs determined by myeloperoxidase immunoreactivity was observed in the ischemic hemisphere, but few PMNs were seen in the contralateral nonischemic hemisphere (data not shown) from all the animals in each treatment group 96 h after transient MCAO. In all the treatment groups, most of the PMNs in the ischemic hemisphere spanned the infarct region (determined by comparing with the adjacent HE section) and its boundary zone (fig. 5A). The number of PMNs in the ischemic hemisphere is shown in figure 5B. UTI, 300,000 U/kg (117 ± 74), but not 100,000 U/kg UTI (220 ± 126) significantly attenuated the number of PMNs in comparison with saline (251 ± 96) (P < 0.05). The difference between both UTI treatment groups did not reach a significant level.
Fig. 6
Fig. 6
Image Tools
Immunohistochemical reaction of nitrotyrosine, a biochemical marker of peroxynitrite, was detected in the ischemic hemisphere but not in the contralateral nonischemic hemisphere (data not shown) 96 h following 2 h of MCA occlusion. Nitrotyrosine immunoreactivity was predominantly located in the entire extent of the infarct region (determined by comparing with the adjacent HE section;fig. 6A). The number of nitrotyrosine-positive cells in the ischemic hemisphere is shown in figure 6B. UTI, 300,000 U/kg (118 ± 44), reduced the number of nitrotyrosine-positive cells compared with saline (243 ± 102) and 100,000 U/kg UTI (207 ± 54) (P < 0.05).
Back to Top | Article Outline

Discussion

Our findings demonstrate that 300,000 U/kg intravenous UTI, administered 10 min before 2-h MCAO, was neuroprotective when evaluated by infarct size, neutrophil infiltration, and nitrotyrosine deposition in the ischemic hemisphere. The treatment tended to improve neurologic outcome but did not reach statistical significance. There are several possible mechanisms for beneficial actions of UTI, which has an antiinflammatory activity, in the brain subjected to focal ischemia–reperfusion.
For the infarct measurement, we used TTC staining at 96 h after MCAO. Liszczak et al.20 have reported that there is 93% correlation between histopathology and TTC staining results in the brain specimens subjected to 2 h of MCAO and following reperfusion for 2–48 h. They also have pointed out the limitation of TTC staining in detecting cerebral infarcts. In chronic infarcts, infiltrating macrophages and other inflammatory cells replace damaged neurons and contribute to the red staining with TTC resulting in discoloration in the white region indicative of infarct. 20 Their finding suggests that TTC staining underestimates infarct area. In our study, however, the white regions were little discolored and clearly delineated as shown in figure 3. Other investigators who evaluated infarct area at 7 days after MCAO demonstrated good correlation between the histopathology and TTC-determined infarct delineation. 21,22 TTC staining at 96 h after MCAO would have not much complicated the determination of infarct area in the current study.
The evaluation of the functional outcome as well as the histologic morphometry of the infarct region is increasingly acknowledged in the experimental stroke model 23 because improvement of the functional outcome would be a primary goal of cerebroprotective therapies. The five-point scale that we used for the motor neurologic evaluation is easy to carry out and is described to be sensitive to lesions of cortex and basal ganglia after transient MCAO 23; nevertheless, the infarct reduction by 300,000 U/kg UTI did not lead to a significant improvement of the motor neurologic deficit, but only demonstrated a trend toward a lower motor deficit in the current study. It is probable that increasing the number of animals in each group would have resulted in a significant improvement of the neurologic scores in the 300,000 U/kg UTI group. Alternatively, the extension of the neurologic scale for higher sensitivity (e.g., the six-point scale including “unilateral circling only if pulled by tail”24) or the use of other kinds of behavioral tasks recognizing functional deficits from cortical or subcortical infarction (e.g., beam balance, prehensile traction, or rotarod 23) might have been required in differentiating between varying degrees of neurologic impairment. Further investigations would therefore be needed to determine the effects of UTI on the motor function after temporary MCAO.
Neutrophil infiltration, the hallmark of acute inflammation, in the ischemic zone occurs to a greater extent in reperfused tissue than in tissue permanently deprived of blood supply in the brain. 3 Our results show that UTI attenuates infiltration of neutrophils in the reperfused brain similarly to the results in the liver and intestine subjected to ischemia–reperfusion obtained by other investigators. 5,11 In rat liver ischemia–reperfusion, UTI treatment decreases tumor necrosis factor α concentrations in the liver tissue, resulting in reduced infiltrating neutrophils. 10 Tumor necrosis factor α recruits and activates neutrophils and leads to increased neutrophil–endothelial adhesion. 3 UTI reduces the production of cytokine-induced neutrophil chemoattractant (the rat form of interleukin 8), blunts neutrophil accumulation, and attenuates injury in the rat liver subjected to ischemia–reperfusion. 6 The transendothelial migration of neutrophil stimulated by interleukin 8 is also inhibited by UTI. 7 UTI is a putative inhibitor of neutrophil chemoattractants in the brain and would modify acute inflammatory response emerging from neutrophil infiltration.
Proteases secreted from activated neutrophils in acute inflammation degrade the extracellular matrix, thus leading to tissue destruction. 25 Neutrophil elastase, the strongest serine protease, degrades elastin, fibronectin, proteoglycan, and collagen as components of the extracellular matrix. 25 The endothelial basement membrane, which restricts the extravasation of granulocytes, is also a target of elastase. 26 UTI has been shown not only to inactivate elastase secreted by neutrophils, but also to suppress the production and secretion of elastase from neutrophils. 8,9 ONO-5046, a neutrophil elastase inhibitor, reduces the size of cerebral infarct elicited by transient MCAO. 27 UTI could reduce neutrophil elastase–mediated tissue injury induced by focal cerebral ischemia–reperfusion.
The weight of evidence from well-conducted studies in the brain supports the concept that activated neutrophils play a causative role in the development of ischemia–reperfusion injury since neutropenia attenuates the size of infarct due to transient MCAO. 3 The number of neutrophils in the ischemic hemisphere reaches a peak between 24 and 96 h after reperfusion in the rodent model of transient MCAO. 28,29 However, neutrophil infiltration is still relatively low when the infarct region evaluated by HE staining is near maximal by 12 h after transient MCAO. 30 Emerich et al.31 argue that neutrophil accumulation after transient MCAO is a secondary pathologic and inflammatory reaction in response to the infarct formation. A direct cause and effect relation between the pathogenesis of infiltrating neutrophils and the infarct formation remains controversial. It is still uncertain to what extent the decrease in neutrophil infiltration with UTI treatment contributes to the decrease in infarct size observed in our investigation.
Inflammatory cells, including neutrophils, generate nitric oxide and oxygen free radicals in the course of ischemia–reperfusion. 32,33 Not only are nitric oxide and superoxide themselves reactive, but they also combine to form the more cytotoxic peroxynitrite, which devastates proteins and tissues. 34 The presence of immunoreactivity of nitrotyrosine, a nitration product of tyrosine residues primarily by peroxynitrite, suggests active nitric oxide and superoxide production and resultant cell damage. It has been reported in the transient MCAO model that immunoreactivity of nitrotyrosine found in the infarct region was decreased by inhibition of a nitric oxide synthase. 35–37 In our model of stroke, diminished nitrotyrosine deposition is indicative of mitigation of acute inflammatory response and coexisting tissue injury mediated by peroxynitrite in the UTI-treated ischemic hemisphere.
During reperfusion, recruited neutrophils aggregate and bind to endothelial cells and plug up the recirculated capillaries, thereby causing perfusion defects after the reestablishment of cerebral circulation and exacerbating ischemic damage. 38 It has been shown that UTI inhibits intercellular adhesion molecule 1 expression on endothelial cells stimulated with tumor necrosis factor α39 and mitigates neutrophil-mediated endothelial injury. 9 UTI also decreases concentrations of endothelin 1 and angiotensin II and attenuates vasoconstriction to improve microcirculation at acute circulatory insufficiency. 40,41 There is a possibility that UTI ameliorates the microcirculatory environment in the reperfused brain with a minimum microvascular plugging. Alternatively, UTI may preserve microcirculation in the penumbra, an area of relatively decreased blood flow lying between the ischemic core and the normal brain during ischemia, likely through its action on microvessels. Effects of UTI on infarct size, neutrophil infiltration, and nitrotyrosine formation in our study might have been more directly related to an improvement in microvascular blood flow.
That a single dose of UTI, administered before a 2-h period of ischemia, was neuroprotective is also our concern. The plasma half-life of 125I-UTI administered intravenously was 9 min in the initial phase of elimination, and 15% of the radioactivity remained in plasma after 1 h in rats. 42 The maximum accumulation of 125I-UTI radioactivity in the murine brain was obtained at 1 min after the intravenous injection, amounting to 0.24% of total amount of administered 125I-UTI. 43 The levels of radioactivity declined rapidly to one sixth and one twenty-fourth of the maximum level after 1 and 4 h, respectively, and no radioactivity was detected 12 h later in the brain. 43 The blood–brain barrier permeability of UTI with a molecular weight of 67,000 is unknown in the injured brain. Kuroiwa et al.44 demonstrated a biphasic opening of the blood–brain barrier to proteins occurring first at 15 min and then at 5–72 h following temporary MCAO. The passage of UTI through the blood–brain barrier might increase shortly after the onset of reperfusion. A 6- to 10-times-higher dose of UTI (300,000 U/kg) in our investigation compared with that in the liver or intestine ischemia–reperfusion 5,6,11 might have contributed to the blood–brain barrier penetration of UTI given before MCAO. We further speculate the higher dose of UTI effectively inhibited intraluminal key events for the initiation of acute inflammatory response (e.g., the expression of inflammatory mediators such as inflammatory cytokines, chemokines, and adhesion molecules).
UTI in the human cerebrospinal fluid increases in patients with brain tumor or subarachnoid hemorrhage, but it is not affected by systemic UTI. 45 A UTI-like immunoreactive substance with trypsin-inhibitory activities has been found in the murine brain, and its content was increased by brain injury. 46 Protease inhibitors derived from neuronal cells have been reported to function as regulators of neurite outgrowth and regeneration. 47 These findings hint that UTI, produced in the brain parenchyma, is involved in repair processes of injured neurons. It is unknown whether exogenous UTI has a similar action in the brain parenchyma in our model of cerebral injury.
In conclusion, prophylactic use of intravenous UTI is neuroprotective against focal ischemia–reperfusion injury in the brain, possibly through the antiinflammatory action. With the available data, precise mechanisms of this neuroprotection remain obscure. UTI has been clinically applied for the treatment of acute pancreatitis and shock without major side effects. 48,49 UTI could potentially be beneficial for patients undergoing surgeries prone to stroke.
Back to Top | Article Outline

References

1. Barone FC, Feuerstein GZ: Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819–34

2. Larrue V, von Kummer RR, Muller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438–41

3. Jean C, Spellman SR, Nussbaum ES, Low WC: Reperfusion injury after focal cerebral ischemia: The role of inflammation and the therapeutic horizon. Neurosurgery 1998; 43: 1382–96

4. Becker KJ: Inflammation and acute stroke. Curr Opin Neurol 1998; 11: 45–9

5. Li XK, Matin AF, Suzuki H, Uno T, Yamaguchi T, Harada Y: Effect of protease inhibitor on ischemia/reperfusion injury of the rat liver. Transplantation 1993; 56: 1331–6

6. Yamaguchi Y, Ohshiro H, Nagao Y, Odawara K, Okabe K, Hidaka H, Ishihara K, Uchino S, Furuhashi T, Yamada S, Mori K, Ogawa M: Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 2000; 94: 107–15

7. Okumura Y, Inoue H, Fujiyama Y, Bamba T: Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats. J Gastroenterol 1995; 30: 379–86

8. Endo S, Inada K, Yamashita H, Takakuwa T, Nakae H, Yamada Y, Kasai T, Taki K, Yoshida M: The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res Commun Chem Pathol Pharmacol 1993; 82: 27–34

9. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I: Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001; 69: 241–7

10. Aihara T, Shiraishi M, Hiroyasu S, Hatsuse K, Mochizuki H, Seki S, Hiraide H, Muto Y: Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-α in the liver. Transplant Proc 1998; 30: 3732–4

11. Li XK, Suzuki H, Kimura T, Kawabe A, Uno T, Harada Y: Ulinastatin, a protease inhibitor, attenuates intestinal ischemia/reperfusion injury. Transplant Proc 1994; 26: 2423–5

12. Nakahama H, Obata K, Sugita M: Ulinastatin ameliorates acute ischemic renal injury in rats. Ren Fail 1996; 18: 893–8

13. Cao ZL, Okazaki Y, Naito K, Ueno T, Natsuaki M, Itoh T: Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart. Ann Thorac Surg 2000; 69: 1121–6

14. Horiguchi T, Harada Y: The effect of protease inhibitor on reperfusion injury after unilateral pulmonary ischemia. Transplantation 1993; 55: 254–8

15. Abe H, Sugino N, Matsuda T, Kanamaru T, Oyanagi S, Mori H: Effect of ulinastatin on delayed neuronal death in the gerbil hippocampus [in Japanese]. Masui 1996; 45: 38–43

16. Yamada K, Goto S, Yoshikawa M, Okamura A, Ushio Y: Continuous intraventricular drug infusion for the in vivo study of transneuronal degeneration in the striatonigral system of the rat. Brain Res Brain Res Protoc 1997; 1: 371–7

17. Prestigiacomo CJ, Kim SC, Connolly ES Jr, Liao H, Yan SF, Pinsky DJ: CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999; 30: 1110–7

18. Mokudai T, Ayoub IA, Sakakibara Y, Lee EJ, Ogilvy CS, Maynard KI: Delayed treatment with nicotinamide (Vitamin B3) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. Stroke 2000; 31: 1679–85

19. Yang Y, Shuaib A, Li Q: Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method. J Neurosci Methods 1998; 84: 9–16

20. Liszczak TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX, Heros RC, Zervas NT: Limitations of tetrazolium salts in delineating infarcted brain. Acta Neuropathol (Berl) 1984; 65: 150–7

21. Sager TN, Hansen AJ, Laursen H: Correlation between N-acetylaspartate levels and histopathologic changes in cortical infarcts of mice after middle cerebral artery occlusion. J Cereb Blood Flow Metab 2000; 20: 780–8

22. Nakamura M, Nakakimura K, Matsumoto M, Sakabe T: Rapid tolerance to focal cerebral ischemia in rats is attenuated by adenosine A1 receptor antagonist. J Cereb Blood Flow Metab 2002; 22: 161–70

23. Zausinger S, Hungerhuber E, Baethmann A, Reulen H, Schmid-Elsaesser R: Neurological impairment in rats after transient middle cerebral artery occlusion: A comparative study under various treatment paradigms. Brain Res 2000; 863: 94–105

24. Menzies SA, Hoff JT, Betz AL: Middle cerebral artery occlusion in rats: A neurological and pathological evaluation of a reproducible model. Neurosurgery 1992; 31: 100–6

25. Owen CA, Campbell EJ: The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999; 65: 137–50

26. Zimmerman BJ, Granger DN: Reperfusion-induced leukocyte infiltration: Role of elastase. Am J Physiol 1990; 259: H390–4

27. Shimakura A, Kamanaka Y, Ikeda Y, Kondo K, Suzuki Y, Umemura K: Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion. Brain Res 2000; 858: 55–60

28. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, Kogure K: Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 1994; 25: 1469–75

29. Stevens SL, Bao J, Hollis J, Lessov NS, Clark WM, Stenzel-Poore MP: The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res 2002; 932: 110–9

30. Zhang RL, Chopp M, Chen H, Garcia JH: Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J Neurol Sci 1994; 125: 3–10

31. Emerich DF, Dean RL3rd, Bartus RT: The role of leukocytes following cerebral ischemia: Pathogenic variable or bystander reaction to emerging infarct? Exp Neurol 2002; 173: 168–81

32. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999; 22: 391–7

33. Forster C, Clark HB, Ross ME, Iadecola C: Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol (Berl) 1999; 97: 215–20

34. Nakazawa H, Fukuyama N, Takizawa S, Tsuji C, Yoshitake M, Ishida H: Nitrotyrosine formation and its role in various pathological conditions. Free Radic Res 2000; 33: 771–84

35. Eliasson MJ, Huang Z, Ferrante RJ, Sasamata M, Molliver ME, Snyder SH, Moskowitz MA: Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J Neurosci 1999; 19: 5910–8

36. Parmentier-Batteur S, Bohme GA, Lerouet D, Zhou-Ding L, Beray V, Margaill I, Plotkine M: Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury. J Cereb Blood Flow Metab 2001; 21: 15–21

37. Gürsoy-Özdemir Y, Bolay H, Saribas O, Dalkara T: Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 2000; 31: 1974–80

38. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM: Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991; 22: 1276–83

39. Aosasa S, Ono S, Seki S, Takayama E, Tadakuma T, Hiraide H, Mochizuki H: Inhibitory effect of protease inhibitor on endothelial cell activation. J Surg Res 1998; 80: 182–7

40. Tani T, Abe H, Endo Y, Hanasawa K, Kodama M: Effects of a urinary trypsin inhibitor on acute circulatory insufficiency after surgical operation. Am J Surg 1998; 175: 142–5

41. Nakajima K, Goto Y: Differentiation of the anti-shock effect of ulinastatin from steroid hormone, by the continuous observation of microcirculation dynamics. Circ Shock 1992; 36: 284–9

42. Jönsson-Berling BM, Ohlsson K: Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scand J Clin Lab Invest 1991; 51: 549–57

43. Sugiki M, Sumi H, Maruyama M, Yoshida E, Mihara H: Clearance and distribution of acid-stable trypsin inhibitor (ASTI). Enzyme 1989; 42: 31–8

44. Kuroiwa T, Ting P, Martinez H, Klatzo I: The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol (Berl) 1985; 68: 122–9

45. Iwama H, Ohmori S, Tsutsumi T: Detectable concentrations of urinary trypsin inhibitor in cerebrospinal fluid. J Neurosurg Anesthesiol 2000; 12: 29–32

46. Shikimi T, Wessel T, Joh TH, Takahashi M, Kaneto H, Hattori K, Takaori S: Demonstration of a human urinary trypsin inhibitor (urinastatin)-like substance in the murine brain. Brain Res 1993; 616: 230–5

47. Monard D: Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends Neurosci 1988; 11: 541–4

48. Takeda K: Protease inhibitors in the treatment of pancreatitis [in Japanese]. Nippon Rinsho 1991; 49: 2125–9

49. Motoki R, Inoue H: Protease inhibitors in shock [in Japanese]. Nippon Rinsho 1991; 49: 2090–4

Cited By:

This article has been cited 27 time(s).

Pediatric Anesthesia
Ulinastatin as a neuroprotective and anti-inflammatory agent in infant piglets model undergoing surgery on hypothermic low-flow cardiopulmonary bypass
Wang, XC; Xue, QH; Yan, FX; Li, LH; Liu, JP; Li, SJ; Hu, SS
Pediatric Anesthesia, 23(3): 209-216.
10.1111/pan.12073
CrossRef
American Journal of Emergency Medicine
Ulinastatin improved cardiac dysfunction after cardiac arrest in New Zealand rabbits
Hu, CL; Li, H; Xia, JM; Li, X; Zeng, XY; Liao, XX; Zhan, H; Jing, XL; Dai, G
American Journal of Emergency Medicine, 31(5): 768-774.
10.1016/j.ajem.2012.11.012
CrossRef
Chest
Protease-antiprotease imbalance in inflammatory diseases in the lung
Inoue, KI; Takano, H; Yoshikawa, TV
Chest, 128(2): 1069.

Laboratory Investigation
Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice
Takano, H; Inoue, K; Shimada, A; Sato, H; Yanagisawa, R; Yoshikawa, T
Laboratory Investigation, 89(7): 833-839.
10.1038/labinvest.2009.35
CrossRef
Protein Expression and Purification
Expression and purification of active recombinant human bikunin in Pichia pastoris
Wang, JQ; Yan, FQ; Wang, DD; Ban, L; Sun, N; Li, CY; Zhang, T; Yan, WQ
Protein Expression and Purification, 60(2): 127-131.
10.1016/j.pep.2008.03.025
CrossRef
International Journal of Molecular Medicine
Antioxidative role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide
Inoue, KI; Takano, H; Yanagisawa, R; Sakurai, M; Shimada, A; Sato, H; Kato, Y; Yoshikawa, T
International Journal of Molecular Medicine, 16(6): 1029-1033.

Life Sciences
Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats
Zhou, Y; Wei, EQ; Fang, SH; Chu, LS; Wang, ML; Zhang, WP; Yu, GL; Ye, YL; Lin, SC; Chen, Z
Life Sciences, 79(): 1645-1656.
10.1016/j.lfs.2006.05.022
CrossRef
Current Topics in Complement II
The Role of Complement in Stroke Therapy
Komotar, RJ; Kim, GH; Often, ML; Hassid, B; Mocco, J; Sughrue, ME; Starke, RM; Mack, WJ; Ducruet, AF; Merkow, MB; Garrett, MC; Connolly, ES
Current Topics in Complement II, 632(): 23-33.
10.1007/978-0-387-78952-1_2
CrossRef
Acta Pharmacologica Sinica
Caffeic acid ameliorates early and delayed brain injuries after focal cerebral ischemia in rats
Zhou, Y; Fang, SH; Ye, YL; Chu, LS; Zhang, WP; Wang, ML; Wei, EQ
Acta Pharmacologica Sinica, 27(9): 1103-1110.
10.1111/j.1745-7254.2006.00406.x
CrossRef
Inflammation Research
Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: A critical review of the literature
Sughrue, ME; Mehra, A; Connolly, ES; D'Ambrosio, AL
Inflammation Research, 53(): 497-508.
10.1007/s00011-004-1282-0
CrossRef
Neuroscience
Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats
Fang, SH; Wei, EQ; Zhou, Y; Wang, ML; Zhang, WP; Yu, GL; Chu, LS; Chen, Z
Neuroscience, 140(3): 969-979.
10.1016/j.neuroscience.2006.02.051
CrossRef
Current Topics in Complement
The complement system: A potential target for stroke therapy
Mocco, J; Sughrue, ME; Ducruet, AF; Komotar, RJ; Sosunov, SA; Connolly, ES
Current Topics in Complement, 586(): 189-201.

Immunopharmacology and Immunotoxicology
Protective role of urinary trypsin inhibitor in lung expression of proinflammatory cytokines accompanied by lethal liver injury in mice
Inoue, K; Takano, H; Sato, H; Yanagisawa, R; Yoshikawa, T
Immunopharmacology and Immunotoxicology, 31(3): 446-450.
10.1080/08923970902769646
CrossRef
Expert Opinion on Investigational Drugs
Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders
Inoue, K; Takano, H
Expert Opinion on Investigational Drugs, 19(4): 513-520.
10.1517/13543781003649533
CrossRef
Neuroscience Letters
A preliminary study of the effects of ulinastatin on early postoperative cognition function in patients undergoing abdominal surgery
Xu, LL; Hu, ZY; Shen, JJ
Neuroscience Letters, 541(): 15-19.
10.1016/j.neulet.2013.02.008
CrossRef
International Journal of Molecular Medicine
Ulinastatin suppresses lipopolysaccharide-induced prostaglandin E-2 synthesis and nitric oxide production through the downregulation of nuclear factor-kappa B in BV2 mouse microglial cells
Sung, YH; Shin, MS; Ko, IG; Kim, SE; Kim, CJ; Ahn, HJ; Yoon, HS; Lee, BJ
International Journal of Molecular Medicine, 31(5): 1030-1036.
10.3892/ijmm.2013.1322
CrossRef
Biomed Research International
Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway
Xu, B; Li, KP; Shen, F; Xiao, HQ; Cai, WS; Li, JL; Liu, QC; Jia, L
Biomed Research International, (): -.
ARTN 437950
CrossRef
Clinical and Experimental Medicine
Kidney post-transplant monitoring of urinary glycosaminoglycans/proteoglycans and monokine induced by IFN-gamma (MIG)
De Muro, P; Faedda, R; Masala, A; Lepedda, AJ; Zinellu, E; Ciccarese, M; Cossu, M; Pala, PG; Satta, RP; Formato, M
Clinical and Experimental Medicine, 13(1): 59-65.
10.1007/s10238-012-0178-5
CrossRef
Acta Pharmacologica Sinica
Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats
Chu, LS; Fang, SH; Zhou, Y; Yu, GL; Wang, ML; Zhang, WP; Wei, EQ
Acta Pharmacologica Sinica, 28(6): 763-772.
10.1111/j.1745-7254.2007.00578.x
CrossRef
Experimental Biology and Medicine
Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide
Inoue, KI; Takano, H; Yanagisawa, R; Sakurai, M; Shimada, A; Yoshino, S; Sato, H; Yoshikawa, T
Experimental Biology and Medicine, 230(4): 281-287.

Journal of Anesthesia
Urinary trypsin inhibitor ameliorates renal tissue oxygenation after ischemic reperfusion in rats
Taie, S; Ueki, M; Chujo, K; Asaga, T; Iwanaga, Y; Ono, J; Maekawa, N
Journal of Anesthesia, 22(2): 149-154.
10.1007/s00540-007-0602-2
CrossRef
Journal of Korean Medical Science
The Anti-Inflammatory Effects of Ulinastatin in Trauma Patients with Hemorrhagic Shock
Park, KH; Lee, KH; Kim, H; Hwang, SO
Journal of Korean Medical Science, 25(1): 128-134.
10.3346/jkms.2010.25.1.128
CrossRef
Cardiology
Urinary Trypsin Inhibitors Afford Cardioprotective Effects through Activation of PI3K-Akt and ERK Signal Transduction and Inhibition of p38 MAPK and JNK
Kim, SJ; Yoo, KY; Jeong, CW; Kim, WM; Lee, HK; Bae, HB; Kwak, SH; Li, M; Lee, J
Cardiology, 114(4): 264-270.
10.1159/000234321
CrossRef
Cardiology
Urinary Trypsin Inhibition: Cardioprotection via the Reperfusion Injury Salvage Kinase Pathway
Hausenloy, DJ
Cardiology, 114(4): 261-263.
10.1159/000234320
CrossRef
Journal of Neuroscience Methods
Statistical mapping of effects of middle cerebral artery occlusion (MCAO) on blood flow and oxygen consumption in porcine brain
Watanabe, H; Sakoh, M; Andersen, F; Rodell, A; Sorensen, JC; Ostergaard, L; Mouridsen, K; Cumming, P
Journal of Neuroscience Methods, 160(1): 109-115.
10.1016/j.jneumeth.2006.08.016
CrossRef
Molecular Pharmacology
Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide
Inoue, KI; Takano, H; Shimada, A; Yanagisawa, R; Sakurai, M; Yoshino, S; Sato, H; Yoshikawa, T
Molecular Pharmacology, 67(3): 673-680.
10.1124/mol.104.005967
CrossRef
Heart Surgery Forum
Inflammatory responses and CNS injury: Implications, prophylaxis, and treatment
Murkin, J
Heart Surgery Forum, 6(4): 193-195.

Back to Top | Article Outline

© 2003 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Images

Share